Purchase Sumatriptan Succinate (Imitrex, Imigran) tablets online
How and where to order Imigran, Imitrex (Sumatriptan) 25 mg, 50 mg, 100 mg tablets online:
Shop: MEDSTORE ONLINE
- 5% discount coupon 5off_2021
Sellers: SUMATRIPTAN STORES
from $2.22 per pill
Imitrex, Imigran (Sumatriptan Succinate) 25 mg, 50 mg, 100 mg tablets
Sumatriptan brand, Imitrex generic, Imigran generic
Visa, Mastercard, AmEx, Bitcoin
Standard airmail and trackable courier service
Worldwide, including USA, UK, Europe, Canada, Australia
Indications and usage:
Imitrex, Imigran (Sumatriptan Succinate) is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
Dosage and administration:
Single dose of Sumatriptan 25 mg, 50 mg, or 100 mg tablet.
A second dose should only be considered if some response to the first dose was observed. Separate doses by at least 2 hours.
Maximum dose in a 24-hour period: 200 mg.
Maximum single dose should not exceed 50 mg in patients with mild to moderate hepatic impairment.
Patients in clinical trials (N = 670) received single oral doses of 140 to 300 mg without significant adverse reactions. Volunteers (N = 174) received single oral doses of 140 to 400 mg without serious adverse reactions.
Overdose in animals has been fatal and has been heralded by convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
The elimination half-life of sumatriptan is approximately 2.5 hours, and therefore monitoring of patients after overdose with Imitrex tablets should continue for at least 12 hours or while symptoms or signs persist.
It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.
Dosage forms and strengths:
Imitrex (Sumatriptan Succinate) tablets 25 mg, 50 mg, 100 mg.
Imigran (Sumatriptan Succinate) tablets 50 mg, 100 mg.
History of coronary artery disease or coronary artery vasospasm.
Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders.
History of stroke, transient ischemic attack, or hemiplegic or basilar migraine.
Peripheral vascular disease.
Ischemic bowel disease.
Recent (within 24 hours) use of another 5-HT1 agonist (e.g., another triptan) or of an ergotamine-containing medication.
Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor.
Hypersensitivity to Imitrex (angioedema and anaphylaxis seen).
Severe hepatic impairment.
Warnings and precautions:
Myocardial ischemia/infarction and Prinzmetal's angina: perform cardiac evaluation in patients with multiple cardiovascular risk factors.
Arrhythmias: discontinue Imitrex pills if occurs.
Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: generally not associated with myocardial ischemia; evaluate for coronary artery disease in patients at high risk.
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: discontinue Imitrex or Imigran if occurs.
Gastrointestinal ischemic reactions and peripheral vasospastic reactions: discontinue Sumatriptan if occurs.
Medication overuse headache: detoxification may be necessary.
Serotonin syndrome: discontinue this medication if occurs.
Seizures: use with caution in patients with epilepsy or a lowered seizure threshold.
Adverse reactions, side effects:
Most common adverse reactions ( >= 2% and > placebo) were paresthesia, warm/cold sensation, chest pain/tightness/pressure and/or heaviness, neck/throat/jaw pain/tightness/pressure, other sensations of pain/pressure/tightness/heaviness, vertigo, and malaise/fatigue.
To report suspected adverse reactions of Imitrex and Imigran (Sumatriptan Succinate) tablets contact GlaxoSmithKline or your local FDA.
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and Imitrex tablets within 24 hours of each other is contraindicated.
Monoamine Oxidase-A inhibitors: MAO-A inhibitors increase systemic exposure by 7-fold. Therefore, the use of sumatriptan tablets in patients receiving MAO-A inhibitors is contraindicated.
Other 5-HT1 agonists: because their vasospastic effects may be additive, coadministration of Imitrex (Sumatriptan Succinate) tablets and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated.
Selective serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors and serotonin syndrome: cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs,
SNRIs, TCAs, and MAO inhibitors.
Use in specific populations:
Pregnancy: based on animal data, may cause fetal harm.
"We provided some exciting changes to the study plan within a couple of weeks of treatment dates and the team stepped up, as usual, and put a plan into place to give us the highest chance of success utilizing the criteria we requested."
Our expert preclinical Surgeons and Interventionalists can assist with human factors assessments and evaluating prototypes for your GLP or nonGLP preclinical studies.